Low Dose Radiotherapy for Osteoarthritis

Purpose

This single institution, multi-site, single arm prospective study will enroll patients with a history of OA and assess changes in pain and function after treatment with LDRT as measured by patient-reported outcomes.

Condition

  • Osteoarthitis

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 18 years or older - Diagnosis of OA >3 months in hips, knees, hands, shoulders, ankles or elbows. - Refractory to standard of care therapies for OA or those who are being considered for more aggressive interventional treatment such as joint replacement, but more conservative treatment is desired. - Provision of signed and dated informed consent.

Exclusion Criteria

  • Unable to reasonably complete study instruments.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Other
Single
Participants will complete study intervention which consists of the BPI-SF, PROMIS Global v1.2, UEFI (for those with joint pain of the upper extremity) and/or LEFS (for those joint pain of the lower extremity) at baseline, 3-month and 1-year follow-up following 1 or 2 courses of standard of care LDRT.
  • Radiation: Low Dose Radiation Therapy
    Participants will complete study intervention which consists of the BPI-SF, PROMIS Global v1.2, UEFI (for those with joint pain of the upper extremity) and/or LEFS (for those joint pain of the lower extremity) at baseline, 3-month and 1-year follow-up following 1 or 2 courses of standard of care LDRT.

Recruiting Locations

Penn Presbyterian Medical Center
Philadelphia, Pennsylvania 19104
Contact:
Marlowe Estioko, BS, MS
267-343-6483
Marlowe.Estioko@Pennmedicine.upenn.edu

Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania 19104
Contact:
Marlowe Estioko, BS, MS
267-343-6483
Marlowe.Estioko@Pennmedicine.upenn.edu

More Details

Status
Recruiting
Sponsor
Abramson Cancer Center at Penn Medicine

Study Contact

Marlowe Estioko, BS, MS
267-343-6483
Marlowe.Estioko@Pennmedicine.upenn.edu

Detailed Description

To evaluate the use of select instruments (BPI-SF, LEFS, UEFI, PROMIS Global) to detect changes in pain, function, and well-being in patients with OA who are refractory to or otherwise unable to receive other standard of care therapies.